서울대학교 중앙도서관

S-Space 소개

My S-Space

로그인이 필요합니다.

Login

S-Space

Browse

Author

Jump to a point in the index

Or type in a year

Sort by
In order
Results/Page
Authors/record

Showing results 1 to 7 of 7

Issue Date	Title / Author(s) / Citation	File	Altmetrics
2013-10	Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer Cortes, J.; Baselga, J.; Im, Y. -H.; Im, S. -A.; Pivot, X.; Ross, G.; Clark, E.; Knott, A.; Swain, S. M. Annals of Oncology, Vol.24 No.10, pp.2630-2635	DOI
2020-05	Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study Schmid, P.; Salgado, R.; Park, Y. H.; Munoz-Couselo, E.; Kim, S. B.; Sohn, J.; Im, S. -A.; Foukakis, T.; Kuemmel, S.; Dent, R.; Yin, L.; Wang, A.; Tryfonidis, K.; Karantza, V.; Cortes, J.; Loi, S. Annals of Oncology, Vol.31 No.5, pp.569-581	DOI
2021-12	ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer Gennari, A.; Andre, F.; Barrios, C. H.; Cortes, J.; de Azambuja, E.; DeMichele, A.; Dent, R.; Fenlon, D.; Gligorov, J.; Hurvitz, S. A.; Im, S. -a.; Krug, D.; Kunz, W. G.; Loi, S.; Penault-Llorca, F.; Ricke, J.; Robson, M.; Rugo, H. S.; Saura, C.; Schmid, P.; Singer, C. F.; Spanic, T.; Tolaney, S. M.; Turner, N. C.; Curigliano, G.; Loibl, S.; Paluch-Shimon, S.; Harbeck, N.; ESMO Guidelines Committee Annals of Oncology, Vol.32 No.12, pp.1475-1495	DOI
2022-02	Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer Schmid, P.; Cortes, J.; Dent, R.; Pusztai, L.; McArthur, H.; Kummel, S.; Bergh, J.; Denkert, C.; Park, Y. H.; Hui, R.; Harbeck, N.; Takahashi, M.; Untch, M.; Fasching, P. A.; Cardoso, F.; Andersen, J.; Patt, D.; Danso, M.; Ferreira, M.; Mouret-Reynier, M-A; Im, S-A; Ahn, J-H; Gion, M.; Baron-Hay, S.; Boileau, J-F; Ding, Y.; Tryfonidis, K.; Aktan, G.; Karantza, V; O'Shaughnessy, J. New England Journal of Medicine, Vol.386 No.6, pp.556-567	DOI
2022-03	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer Cortes, J.; Kim, S.-B.; Chung, W.-P.; Im, S.-A.; Park, Y.H.; Hegg, R.; Kim, M.H.; Tseng, L.-M.; Petry, V.; Chung, C.-F.; Iwata, H.; Hamilton, E.; Curigliano, G.; Xu, B.; Huang, C.-S.; Kim, J.H.; Chiu, J.W.Y.; Pedrini, J.L.; Lee, C.; Liu, Y.; Cathcart, J.; Bako, E.; Verma, S.; Hurvitz, S.A. New England Journal of Medicine, Vol.386 No.12, pp.1142-1154	DOI
2024-05	Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial Hurvitz, S.A.; Kim, S.-B.; Chung, W.-P.; Im, S.-A.; Park, Y.H.; Hegg, R.; Kim, M.-H.; Tseng, L.-M.; Petry, V.; Chung, C.-F.; Iwata, H.; Hamilton, E.; Curigliano, G.; Xu, B.; Egorov, A.; Liu, Y.; Cathcart, J.; Bako, E.; Tecson, K.; Verma, S.; Cortes, J. ESMO Open, Vol.9 No.5, p. 102924	DOI
2024-07	IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative breast cancer Dent, R.; Andre, F.; Goncalves, A.; Martin, M.; Schmid, P.; Schutz, F.; Kummel, S.; Swain, S.M.; Bilici, A.; Loirat, D.; Villalobos, Valencia R.; Im, S.-A.; Park, Y.H.; De, Laurentis M.; Colleoni, M.; Guarneri, V.; Bianchini, G.; Li, H.; Kirchmayer, Machackova Z.; Mouta, J.; Deurloo, R.; Gan, X.; Fan, M.; Mani, A.; Swat, A.; Cortes, J. Annals of Oncology, Vol.35 No.7, pp.630-642	DOI

1